Clinical trials for Psoriasis

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Psoriasis. For all clinical trials, go to clinical trials search

This list shows clinical trials for Psoriasis

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Psoriasis
Title Recruitment status Location
A phase 3, multi-center,open-label continuation study in moderate to severe chronic plaque psoriasis subjects who completed a preceding psoriasis study with ABT-874. - ND Not Recruiting United Kingdom
A study to investigate what effects FX125L (taken by mouth) has on adults with chronic inflammatory diseases Not Recruiting United Kingdom
Psoriasis Not Recruiting United Kingdom
A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 AND 1 SUBCUTANEOUS DOSE OF ETANERCEPT IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS Not Recruiting United Kingdom
A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 AND 1 SUBCUTANEOUS DOSE OF ETANERCEPT IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS Not Recruiting United Kingdom
A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with moderate to severe psoriasis with a 12 week treatment extension for PASI 50 responders. Not Recruiting United Kingdom
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects with Moderate to Severe, Chronic Plaque-Type Psoriasis Not Recruiting United Kingdom
Assessment of the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab Not Recruiting United Kingdom
Psoriasis Not Recruiting United Kingdom
A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination with Topical Treatment (Calcipotriol/Betamethasone) in Subjects with Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE) Incorporating Amendment 1, Administrative Change 1 and Photographic Documentation Amendment 1 for France, Germany, and The Netherlands - BELIEVE Not Recruiting United Kingdom

Page last reviewed:

Next review due: